Batra Neelu, Tu Mei-Juan, Yu Ai-Ming
Department of Biochemistry and Molecular Medicine, UC Davis School of Medicine, Sacramento, CA, USA.
Methods Mol Biol. 2025;2965:489-500. doi: 10.1007/978-1-0716-4742-4_26.
Novel in vivo approaches for manufacturing RNA agents are warranted to complement conventional methods such as in vitro transcription and chemical synthesis. Recently, we have identified and utilized unique tRNA-fused pre-miRNA carriers to establish a robust RNA molecular bioengineering technology that allows one to consistently and efficiently produce target, bioengineered or biologic RNA molecules bearing small interfering RNA (siRNA) payloads (BioRNA/siRNA). Here, we describe a streamlined method with a detailed protocol for the rational design, molecular cloning, heterologous overexpression, and chromatography purification of large quantity (multi-milligrams from 0.25 L of bacterial culture) and high quality (> 98% homogeneity and <5 endotoxin unit/μg RNA) of target BioRNA/siRNA molecules that are ready for basic research as well as experimental therapy.
开发用于制造RNA制剂的新型体内方法,对于补充诸如体外转录和化学合成等传统方法很有必要。最近,我们已经鉴定并利用了独特的tRNA融合前体miRNA载体,建立了一种强大的RNA分子生物工程技术,该技术能够持续、高效地生产携带小干扰RNA(siRNA)载荷的靶向、生物工程或生物RNA分子(BioRNA/siRNA)。在此,我们描述了一种简化方法及详细方案,用于合理设计、分子克隆、异源过表达以及色谱纯化大量(从0.25 L细菌培养物中获得数毫克)和高质量(>98%纯度且<5内毒素单位/μg RNA)的靶向BioRNA/siRNA分子,这些分子可用于基础研究以及实验治疗。